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Background: Hepatocellular carcinoma (HCC) remains a global health problem with unique diagnostic and
therapeutic challenges, including difficulties in identifying the highest risk patients. Previous work from our lab
has established the murine multidrug resistance-2 mouse (MDR2) model of HCC as a reasonable preclinical
model that parallels the changes seen in human inflammatory associated HCC. The purpose of this study is to
evaluate modalities of PET/CT in MDR2−/− mice in order to facilitate therapeutic translational studies from bench
to bedside.
Methods: 18F-FDG and 11C-acetate PET/CT was performed on 12 m MDR2−/− mice (n = 3/tracer) with HCC and 12 m
MDR2−/+ control mice (n = 3/tracer) without HCC. To compare PET/CT to biological markers of HCC and cellular
function, serum alpha-fetoprotein (AFP), lysophosphatidic acid (LPA), cAMP and hepatic tumor necrosis factor α
(TNFα) were quantified in 3-12 m MDR2−/− (n = 10) mice using commercially available ELISA analysis. To translate
results in mice to patients 11C-acetate PET/CT was also performed in 8 patents suspected of HCC recurrence following
treatment and currently on the liver transplant wait list.
Results: Hepatic18F-FDG metabolism was not significantly increased in MDR2−/− mice. In contrast, hepatic 11C-acetate
metabolism was significantly elevated in MDR2−/− mice when compared to MDR2−/+ controls. Serum AFP and LPA
levels increased in MDR2−/− mice contemporaneous with the emergence of HCC. This was accompanied by a
significant decrease in serum cAMP levels and an increase in hepatic TNFα. In patients suspected of HCC recurrence
there were 5 true positives, 2 true negatives and 1 suspected false 11C-acetate negative.
Conclusions: Hepatic 11C-acetate PET/CT tracks well with HCC in MDR2−/− mice and patients with underlying liver
disease. Consequently 11C-acetate PET/CT is well suited to study 1) HCC emergence/progression in patients and
2) reduce animal numbers required to study new chemotherapeutics in murine models of HCC.Background
Hepatocellular carcinoma (HCC) is a primary cancer
of the liver that most often develops in identifiable pa-
tients with underlying liver disease, like hepatitis. HCC
is the fourth most common cancer in the world with
age-normalized incidence rates of 2.1 per 100,000 in
North America [1, 2]. The risk of HCC is thought to
be associated with inflammatory changes within the liver* Correspondence: nskill@iupui.edu
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unless otherwise stated.microenvironment which extends over a protracted period
of time, with cirrhosis and chronic hepatitis (B and C)
accounting for approximately 50 % of all HCC [3]. At our
institution, we have a patient population with increased
risk that present for treatment before emergence of HCC.
This puts our institution in a unique position to evalu-
ate biomarkers of cancer risk along with novel diag-
nostic tests that would improve stratification in patients
with the highest likelihood of cancer, thus resulting in im-
proved diagnostic and treatment paradigms to be applied.
Our ability to impact patient outcomes in HCC rests in
three key areas: 1) biomarkers of cancer risk, 2) improve-
ments in diagnostic imaging, and 3) improved therapeuticThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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sues and investigates the use of lysophosphatidic acid
(LPA) profile analysis and PET/CT imaging in the
multiple drug resistance-2 (MDR-2) knockout mouse
model of HCC.
MDR2 is a membrane-associated protein linked to
lipid transportation and is increased in HCC cell lines
and tumors [4, 5]. Previous studies have demonstrated
in vitro MDR2 expression is increased in response to
chemotherapeutic agents and that HCC develops spon-
taneously in MDR2−/− mice [6–11]. More recently we
have shown that HCC tumor burden can be reduced by
administration of the commercially available LPA bio-
synthesis/signaling inhibitor BrP-LPA [6] and confirmed
the use of MDR2−/− mice as a model for clinical path-
ologies [12–16]. This current study builds on our use of
macroscopic measurements of HCC as indicators of
disease progression, and evaluates non-invasive markers
and imaging in MDR2−/− mice in order to validate tools
pursuant to accurately measuring response to chemo-
therapeutic agents in future studies.
Currently, the first line therapy for patients not eligible
for resection or liver transplantation is sorafenib chemo-
therapy [17]. However, sorafenib is associated with a
meager improvement in overall survival compared to
supportive care alone. Recent reports have shown resist-
ance to sorafenib in liver cells linked to phenotypic
changes consistent with advanced invasion [18], and that
sorafenib response is related to deregulation of mitochon-
dria fusion-related protein optic atrophy 1 (OPA1) and
reduction in Phosphatase and tensin homolog (PTEN)
expression [19, 20]. The documented stable disease rate
associated with sorafenib suggests that it would perhaps
be more appropriate as a chemoprevention agent rather
than treating established disease. To facilitate these
studies an accurate suite of modalities to evaluate pre-
clinical therapeutic response in vivo is required, including
methods to evaluate tumor burden and response to treat-
ment. Accordingly, to better understand the MDR2−/−
model of HCC, MDR2−/− mice underwent testing for:
1) HCC biomarker serum alpha fetoprotein (AFP) ELISA;
2) oxidative metabolism by 11C-acetate PET/CT; 3) glyco-
lytic metabolism by 18 F-FDG PET/CT; 4) lipid metabol-
ism by lysophosphatidic acid variant profile tandem mass
spectroscopy; 5) cellular signaling by circulating cAMP
ELISA and 6) inflammatory cytokine modulation by hep-
atic TNFα ELISA. We found that all modalities, except
glycolytic metabolism via 18 F-FDG PET/CT, differentiated
mice with HCC from those without, thus demonstrating
potential modalities to monitor HCC development and
treatment in MDR2−/− mice. In addition, to confirm the
relevance of 11C-acetate PET/CT for HCC in mice 11C-
acetate PET/CT was performed in 8 patients with sus-
pected recurrent HCC following standard of care therapy.We found that 5 of 8 patients were true positives, 2 of 8
were true negatives, and one false negative patient. This
information confirms the potential of 11C-acetate PET/CT
in murine studies to develop novel and new therapies of
treatment.Methods
Animals
MDR2−/− Mice
All studies were carried out in accordance with, and
approval from, the Institutional Animal Care and Use
Committee of Indiana University School of Medicine,
the U.S. Department of Agriculture’s Animal Welfare
Act (9 CFR Parts 1, 2, and 3) and the Guide for the Care
and Use of Laboratory Animals [21]. Multiple drug re-
sistance gene null mice were purchased from Jackson
Labs, MA (FVB.129P2-Abcb4tm1Bor/J) and breeding colonies
were established within the Indiana University Laboratory
Animal Research Centre. MDR2−/− mice originating from
the Friend virus B-type/N (FVB) background have been
found to develop HCC more efficiently then mice from
C57BL6 background [22]. Mice were maintained on
Teklad Lab Animal Diet TD 2014 (Harlan Laboratories
USA) with ad libitum access to tap water, and a 12:12
(light:dark) hour photoperiod at 22-24 °C. MDR2−/− mice
lack the ability to secrete phospholipids into the bile from
the liver and they develop degenerative liver disease, fibro-
sis and portal inflammation. At an early age MDR2−/−
mice are used as a model of primary sclerosing cholangitis
(PSC) and that treatment with β-blockers reduce fibrosis
[23]. PSC is an underlying etiology of HCC in patients.
HCC develops in MDR2−/− at approximately 1 year. To
date, the precise mechanism connecting MDR2 to fi-
brosis is not yet known; however, recent studies sug-
gest that NADPH oxidases NOX4 may play a role
[24]. Mice were distributed in to three groups for 1)
analysis of serum and tissue markers of HCC (n = 10),
2) for 11C-acetate PET/CT imaging (n = 3) and 3) for
18 F-FDG PET/CT (n = 3).
Expression of the mutant MDR2 gene was confirmed by
PCR of tail DNA samples. Mutant and wild-type primers
are described by the Jackson Labs (CGG CGA GGA TCT
CGT CGT GAC CCA and GCG ATA CCG TAA AGC
ACG AGG AAG and GCT GAG ATG GAT CTT GAG
and GTC GAG TAG CCA GAT GAT GG, respectively).
PCR reactions for wild type and mutant MDR2 gene were
performed separately, but with identical amplification con-
ditions (i.e. Melting 94 °C 30 sec, appealing 59 °C 1 min,
elongation 68 °C 1 min × 25). Products were separated on
1 % agarose TBE ethidium bromide gels and visualized
under UV illumination. FVB wild type mice were also pur-
chased form Jackson labs (FVB/NJ) and were used as
controls.
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Alpha Feto Protein (AFP) Serum AFP levels were quan-
tified in 3-18 M MDR2−/− and MDR2−/+ mice using a
commercial ELISA (USCN Life Science Inc. Wuhan) as
per manufactures instructions.Cyclic Adenosine Mono Phosphate (cAMP) Serum
from 3 to 18 M MDR2−/− and MDR2−/+ mice were quan-
tified for cAMP using a commercially available ELISA kit
(Invitrogen, CA) as per manufacturer’s instructions.Tumor Necrosis Factor Alpha (TNFα) 5 % (w/v) liver
homogenates from 3 to 18 M MDR2−/− and MDR2−/+
mice were quantified for TNFα using a commercial mur-
ine TNFα ELISA (Invitrogen, CA) as per manufacturer’s
instructions.LPA MS/MS analysis Was performed by Covance
Laboratories, IN. under a fee for service contract. MS
analyses were performed using a API-4000 (Applied
Biosystems, Forster City, CA). Typical operating parame-
ters were as follows: collision gas (CAD) 8 units, curtain
gas (CUR) 10 psi, ion source gas 1 (GS1) 15 psi, ion source
gas 2 (GS2) 35 psi, electrospray voltage 5000 V with posi-
tive ion MRM mode or −4200 V with negative ion MRM
mode, and a temperature of heater at 500 °C. Multiple
reaction monitoring (MRM) mode was used for measure-
ment of LPAs. Negative and positive monitoring ions have
been described previously [25]. Samples (10 μL) were
loaded through a LC system (Agilent 1100) with an auto
sampler. A TARGA C18 5 μM, 2.1 mm ID× 10 mm TR-
0121-C185 (Higgins Analytical, Southborough, MA USA)
HPLC column was used for the separation of lyso-
phospholipids. The mobile phase A was MeOH/water/
NH4OH (90:10:0.1, v/v/v) and the mobile phase B was
5 mM ammonium acetate in MeOH/water (90:10, v/v).
The HPLC separations was 12 min/sample using the fol-
lowing scheme: 1) 100 % A for 3 min with a flow rate at
0.2 mL/min; 2) the mobile phase was changed from 100 %
A to 100 % B over 2 min with the flow rate increased from
0.2 to 0.8 mL/min; 3) a constant flow rate of 0.8 mL/min
for 5 min; 4) the mobile phase was changed from 100 % B
to 100 % A in 1 min with the flow rate decreased from 0.8
to 0.2 mL/min; and 5) constant flow rate of 0.2 mL/min
for 1 min.Fibrosis scoring Hepatic sections (5 μm) were Mason
Trichrome stained for collagen and fibrosis scoring was
quantified using ImageJ software (http://rsb.info.nih.gov/ij/)
as described previously [26].In vivo imaging
PET and CT imaging
For glycolysis imaging, conscious mice were injected with
7.5 ± 0.36 MBq of 18 F-FDG via tail vein and returned to
an isothermal cage for 30 min to allow for conscious
tracer uptake and enzymatic trapping. For oxidative
phosphorylation imaging, mice were anesthetized (see
below) placed on the scanner bed and injected with 6.6 ±
0.79 MBq of 11C-acetate via tail vein once the scanner
acquisition sequence had initiated. In all cases, anaesthetic
induction was achieved with 3-5 % isoflurane gas (balance
medical air), where mice were placed on the scanners im-
aging bed, and aesthetic plane was maintained with 1-
3 % isoflurane gas. Dynamic high resolution 18 F-FDG and
11C-acetate Positron Emission Tomography [27] images
were acquired in list-mode for 30 and 60 min, respectively,
using the IndyPETIII small animal PET scanner [27]
where animals were maintained isothermal by use of a
750 W convective header (P/N VH2 EH1-0020-01,
Vornado Inc, USA). At the end of the PET imaging ses-
sion, the mouse and carbon fiber bed were transferred to
small animal computed tomography (CT) imager (R9, GE
Healthcare, Inc USA), where whole body CT images were
acquired in two bed positions using a tube voltage, current
and shutter speed of 55kVp, 1000 mA and 100 ms, re-
spectively. Post-acquisition, 18 F-FDG and 11C-acetate
images were reconstructed using filtered back projection
(FBP) according to published methods [28] with a 60 mm
field of view into a single static 3D image volume, and
dynamic 4D image series (3D image volumes with time),
respectively. In all cases, CT images were reconstructed
into a calibrated single 3D image volume using FBP and
a 4x4 binning according to manufacturer, yielding a final
effective isotropic resolution of 0.160 mm.
Image analysis
In all cases, CT images were co-registered to 18 F-FDG or
11C-acetate PET image volumes using a Analyze 11.0
(AnalyzeDirect) software based on the maximum entropy
and mutual information algorithm described previously
[29]. Manual whole liver segmentation was performed on
registered CT image volumes (Analyze 11.0, AnalyzeDirect).
To permit kinetic modelling, left ventricular cavities were
also manually segmented for 11C-acetate studies to pro-
vide an image derived arterial input function. Static 18 F-FDG
PET images were analysed for percent injected dose per
gram (%ID/g) according to published methods [30], while
dynamic 11C-acetate PET were analysed for liver metabol-
ism by applying a 2 compartment kinetic model described
previously [31].
Human 11C-acetate PET/CT
Was performed in accordance with FDA Physician-Sponsored
Expanded Access IND #118204 (James W. Fletcher, M.D.,
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CT was obtained prior to imaging in accordance with In-
diana University IRB protocol #1407718337. Children
were not included due to increased protection mandated
to children by US department of health and human ser-
vices (45 CFR 46.405). There is a low propensity of HCC
in children and the 11C-acetate radiation exposure does
not provide a direct benefit to the individual subject. 11C-
acetate was prepared as described by Mock et al. [32].
The 11C-Acetate radiopharmaceutical was administered
intravenously at a dose of 20–40 mCi (0.74-1.5 GBq). In-
clusion criteria: patient’s with suspected clinical recur-
rence of HCC after initial radiation or surgical treatment,
and who were candidates for surgery or systemic therapy
depending on the PET/CT 11C-acetate identified location
and extent of recurrence (Patients with elevated AFP >
200 or rising AFP but without any measureable disease
burden). Patients with a prototype lesion(s) based on CT
or MRI imaging that have addition lesions of unclear
clinical significance because they are sub-centimeter. Pa-
tients who meet transplant eligibility for transplant with
a diagnosis of cancer based on AASLD criteria, but in
whom our current metastatic evaluation is lacking both
sensitivity and specificity. Patients with whom clinical
variables are worrisome for a greater disease burden than
that suggested by our current imaging standards (CT or
MRI) (i.e. acute elevation in AFP, portal vein thrombosis,
multifocal lesions, tumor size > 4.5 cm). Patients trans-
planted with cancer or whom the explant shows a greater
disease burden than that noted on pre-transplant im-
aging putting them at a higher risk for cancer recurrence.
Eight patients received 11C-acetate from 9/13/13 through
3/17/2014. Image analysis and interpretation followed
the general recommendations of the Society of Nuclear
Medicine (SNMMI) and the European Association of
Nuclear Medicine (EANM) in their procedure guide-
lines for PET/CT tumor imaging with other agents. A
nuclear medicine physician visually evaluated normal
bio-distributions and abnormal accumulations. Tracer
accumulation in structures that did not take up the tracer
physiologically, or accumulations higher than background
activity, was considered to be pathological. Clearly demar-
cated findings with higher tracer uptake were classified as
definitely positive for enhanced radiotracer uptake, and
thus indicative of malignancy. SUVmax and SUVpeak were
obtained in areas judged to represent abnormal uptake as
semi-quantitative measures of tracer bio-distribution. In
this study measurement of 11C-acetate uptake was limited
to the liver. Organ specific 11C-acetate uptake in humans
has previously been described by Seltzer et al. (2004) [33].
Statistical analysis
Biochemical and imaging data are presented as Mean ±
1S.E.M. Determinations of parameter estimates for tracerkinetic models by non-linear regression were performed
with custom software developed in IDL 7.1 (Visual Infor-
mation Solutions). Statistical comparison of cohorts for
analytes and metabolic parameters were performed using
a 2-tailed unpaired Student’s t-test using Excel 12.0
(Microsoft, Inc.). In all cases, statistical significance was
taken at the p < 0.05 level. Data correlations were deter-
mined using Pearson correlation coefficient (two variables
are assumed to have a bivariate normal distribution)
analysis and Excel 12.0 (Microsoft, Inc). Correlations
amongst 11C-acetate uptake, serum LPA/AFP and hepatic
TNFα was not undertaken.
Results
MDR2−/− Mice
Mouse genotype was confirmed by RT-PCR (Fig. 1a).
There was no difference in body or tissue weights amongst
MDR2−/− mice, FVB and MDR2−/+ control mice. Hep-
atic tumors were discovered in 100 % of MDR2−/− (Fig. 1c)
mice but were not observed in MDR2−/+ (Fig. 1b) mice.
Mouse tumor burden increased with age and ranged from
0 mm at 9mo to 7.3 ± 2.4, 15.5 ± 1.5 and 14.33 ± 2.7 mm
at 12, 15 and 18mo, respectively (Fig. 1d, Table 1).
Serum AFP
Serum AFP levels are typically raised in patients with
HCC, although the sensitivity and specificity of this bio-
marker is low [34]. In MDR2−/+mice, that don’t develop
HCC, serum AFP levels were not significantly increased
when compared to FVB controls (Fig. 2a). In contrast, and
similarly observed in humans with HCC, serum AFP was
significantly (p = 0.048, n = 10) increased in MDR2−/−
mice (58 ± 15 ng/ml) when compared to control mice
(35 ± 5 ng/ml) (Fig. 2a); however, this increase was not
uniform across all mice studied. Serum AFP levels were
significantly elevated (40 ± 9 ng/ml) in 63 % of MDR2−/−
mice, with little correlation between serum AFP levels and
tumor burden (R2 = 0.17, n = 10).
Serum cAMP
Although not measured for clinical diagnosis of HCC,
cAMP has previously been linked to HCC [35]. cAMP is
a ubiquitous secondary signaling molecule and can be
measured using commercially available functional assays.
Serum cAMP levels were markedly reduced in MDR2−/−
mice as they aged resulting in a significantly reduced
circulating level contemporaneous with the detection of
HCC. Levels reduced from a high at 3mo of 0.45 ±
0.14 nmol/ml to a low of 0.06 ± 0.03 nmol/ml at 12 m
(Fig. 2b).
Hepatic TNFα
TNFα, an inflammatory cytokine, levels have well corre-
lated with HCC [36]. Murine serum levels of TNFα are
Fig. 1 Genotyping of mice and tumor burden in MDR2 mice. a) Mouse genotype was confirmed by PCR. 380 bp represented wild type MDR2
gene 180 bp product represents mutant MDR2 gene, mwm equals 100 bp standard. b) 12 mo MDR2−/+ control mouse liver. c) 12 mo MDR2−/−
liver and d) Tumor burden in MDR2−/− mice 12-18 mo
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able ELISA assays and thus hepatic TNFα levels were
quantified directly. Hepatic TNFα levels increased pro-
gressively with age in MDR2−/− mice, and increased
from low levels of 1 ± 0.2 pg/mg at 3mo to 5.37 ± 0.8,
7.08 ± 1.25 and 7.3 ± 1.1 at 6, 9 and 12mo, respectively
(Fig. 2c).
Fibrosis
There was a markedly increased staining for collagen in
livers MDR2−/− mice when compared to MDR2−/+ and
FVB control mice (Fig. 2D-E). Quantification of staining
using ImageJ software showed a 140 % increase over
controls.
HCC histology
The tumors consist of large cells with abundant eosino-
philic cytoplasm and prominent central nuclei arranged
in a trabecular pattern. Some tumor cells show steatosis.
These features are characteristic of hepatocellular differ-
entiation. Distinct from biliary or metastatic tumors, no
gland formation is seen.Table 1 MDR2 mouse characteristics
Mouse
strain (n)
Time to HCC
development (Months)
Histology
FVB (10) N/A Normal hepatic histology
MDR2−/+ (10) N/A Normal hepatic histology
MDR2−/− (10) 9-12 M Background liver: Modera
Tumor: Large cells with ab
prominent central nuclei
tumor cells showed evidePET/CT Imaging To non-invasively monitor tumour
emergence and growth in MDR2−/−, and to advance our
knowledge with this modality for future therapeutic
work, PET/CT imaging was performed on MDR2−/− and
MDR2−/+ mice (n = 3).18 F-FDG PET/CT
Clinical monitoring of HCC disease for staging and de-
termination of partial or complete liver transplants have
been reported [37–40]. To evaluate the role of glycolytic
metabolism in HCC, static 18 F-FDG PET/CT scans were
conducted on MDR2−/− and control mice. There was no
significant difference in 18 F-FDG uptake in the livers of
MDR2−/− (3.61 ± 0.97 %ID/g) mice when compared to
wild type controls (4.3 ± 0.6 %ID/g, p = 0.58, n = 3/
group) (Fig. 3a-c). In contrast, cardiac 18 F-FDG uptake
were significantly higher in MDR2−/− mice when com-
pared to controls (14.9 ± 4.9 vs. 5 ± 0.7, p = 0.05, n = 3/
group respectively) (Fig. 3a-b + d). The rationale behind
an increase in cardiac 18 F-FDG is beyond the scope of this
manuscript, but we include the data for disseminationMaximum tumor size (mm)
N/A
N/A
te hepatic fibrosis. 12 M – 7 ± 1
undant eosinophilic cytoplasm and
arranged in a trabecular pattern. Some
nce of steatosis.
15 M – 15 ± 1
18 M – 14 ± 2
Fig. 2 Serum AFP and cAMP and hepatic TNFα are modulated contemporaneously with HCC in MDR2−/− mice. Serum AFP and cAMP
and hepatic TNFα were quantified in MDR2−/− mice prior to emergence of HCC at 12 mo. a) Serum AFP levels increased in MDR2−/− mice
concomitant with the emergence of HCC. b) Serum cAMP levels significantly reduced prior to the emergence of HCC. c) Hepatic TNFα levels
were significantly increased prior to emergence of HCC. D-E) Representative micrographs of MDR2−/− (D) FVB and (E) control mouse livers.
Collagen staining (blue) was markedly increased in 12 mo MDR2−/− mice when compared to 12 mo MDR2−/+ controls
Territo et al. BMC Medical Imaging  (2015) 15:15 Page 6 of 12purposes so that others may evaluate the relevance and
importance.
11C-Acetate PET/CT
Elevated substrate level oxidative phosphorylations, in the
absence of glycolytic contributions, have been reported in1
1
A
1
1 1
B
C
Fig. 3 18F-FDG PET/CT imaging of MDR2−/−, MDR2−/+ and FVB wild type m
control mice. a) Representative 18 F-FDG PET/CT parametric (%ID/g) images
(%ID/g) images of FVB control mouse (student’s t test p = 0.26, n = 3/group
mouse when compared to controls. d) Heart 18 F-FDG uptake was significa
t test p = 0.04, n = 3/group)clinical HCC [37–40]. To monitor substrate level oxida-
tive phosphorylation in HCC, dynamic 11C-acetate PET/
CT scans were conducted on MDR2−/− and control mice.
Hepatic 11C-acetate metabolic rates were statistically
higher in MDR2−/− (0.62 ± 0.04 ml/g.min) mice when
compared to wild-type control mice (0.49 ± 0.02 ml/g.min,0
5.0
2.50
3.75
1.25
F
D
G
 U
ptake (%
ID
/g)
D
ice: PET/CT imaging was performed on 12 mo MDR2−/− and FVB
of MDR2−/− mouse. b) Representative 18 F-FDG PET/CT parametric
). c) Liver 18 F-FDG uptake was not significantly greater in MDR2 KO
ntly greater in MDR2 KO mouse when compared to controls (student’s
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were observed between MDR2−/+ and FVB control
(p > 0.05).
Serum LPA
Serum 20:4LPA and 18:2LPA levels where significantly in-
creased in MDR2−/− mice simultaneous with HCC emer-
gence. Levels increased from 129 ± 87nM to 141 ± 116nM
in FVB controls to 1177 ± 151 nM and 1331 ± 121nM in
12 m MDR2−/− mice for 20:4LPA and 18:2 LPA, respect-
ively (p < 0.01, n = 10). There was no significant difference
in LPA precursor LPC for either variant (p > 0.05, n = 10,
Fig. 5a). This increase in LPA in the absence of an increase
in precursor LPC demonstrates a definite increase in LPA
biosynthesis verified by a marked increase in the LPA to
LPC ratio for both 20:4LPA and 18:2LPA (Fig. 5b).
Human 11C-acetate PET/CT
The indication in all except one patient was prior diagno-
sis of HCC with suspicion for recurrent disease because
of rising AFP and indeterminate CT and MRI findings.
One patient had rapidly rising AFP but no radiologic
abnormality on CT or MRI. Most subjects had had prior
treatment with either 90Y-radioembolization or external
beam therapy. All patients were on waiting list for liver
transplant. There were five True positive exam results,
two probable True negative exam results and one likely
false negative exam result. Following the 11C-acetate
exam the following actions were initiated: radio embo-
lization with 90Y for recurrent disease (n = 1); treatment
of recurrent disease with Stereotactic body radiotherapy
(n = 1); removal from transplant program list due to
unsuspected distant skeletal metastases (n = 1); and con-
tinued monitoring (n = 8).
Discussion
Hepatocellular carcinoma is one of the leading causes of
deaths associated with cancer, with greater than 700,0000
1.
0.
1.
0.
1
1 1
A
1
1 1
B
Fig. 4 11C-acetate PET/CT imaging of MDR2−/−, MDR2−/+ and FVB wild typ
and FVB control mice. a) Representative 11C-acetate PET/CT parametric (ml/
parametric (ml/g.min) images of FVB control mouse. c) Hepatic 11C-acetate
compared to controls (student’s t test p < 0.05, n = 3/group)new cases diagnosed annually, and more than 600,000
deaths worldwide attributed to HCC per annum [41].
Among malignancies, HCC is the fourth most common
cancer worldwide [1, 2] with an age-normalized inci-
dence rate of 17, 42, 46, 62, and 371 per 100,000 in the
United States, Africa, European Union, South East Asia,
and China, respectively [42].
Provided this, there is a distinct need to improve diag-
nostic and treatment options available for patients with
HCC [43]. The potential benefits of 11C-acetate PET/CT
are numerous. In patients with elevated AFP > 200 or
rising AFP but without any measureable disease burden
11C-acetate opens up the possibility of detecting occult
or subclinical cancer within a high risk diseased liver. In
patients with a prototype lesion(s) based on CT or MRI
imaging that have addition lesions of unclear clinical
significance because they are sub-centimeter 11C-acetate
imaging opens up the possibility to put sub-centimeter
lesions in perspective in patients who otherwise meet
imaging criteria for HCC, thereby improving our ability
to evaluate overall disease burden. In patients who meet
transplant eligibility for transplant with a diagnosis of
cancer based on AASLD criteria, but in whom our
current metastatic evaluation is lacking both sensitivity
and specificity 11C-acetate imaging will facilitate improved
organ allocation and reduce post-transplant recurrence.
In patients in whom clinical variables are worrisome for a
greater disease burden than that suggested by our current
imaging standards (CT or MRI) (i.e. acute elevation in
AFP, portal vein thrombosis, multifocal lesions, tumor
size > 4.5 cm) 11C-acetate opens up the possibility of
improving our understanding of disease burden. In pa-
tients transplanted with cancer in whom the explant shows
a greater disease burden than that noted on pre-transplant
imaging putting them at a higher risk for cancer recur-
rence 11C-acetate imaging may provide some advantage
over CT or MRI when used for surveillance in post-
transplant patients considered at higher risk for recurrence5
75
13
38
A
cetate M
etabolic R
ate (m
l/g.m
in)
C
e mice. 11C-acetate PET/CT imaging was performed on 12 mo MDR2−/−
g.min) images of MDR2−/− mouse. b) Representative 11C-acetate PET/CT
metabolic rate was significantly greater in MDR2−/− mouse when
Fig. 5 LPA variant profile is modulated prior to HCC emergence in MDR2−/− mice. a) Serum levels of LPA and LPC variants were determined by
LC/MS. There was a significant increase in 18:2 LPA and 20:4 LPA in MDR2−/− mice prior to the emergence of HCC at 12 mo. LPA variant levels
were maximal at 12 mo. b) Calculation of the 20:4 LPC/20:4 LPA ratios showed a dramatic change indicative of increased ATX activity
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sant protocols post-transplant would become relevant.
The MDR2-/- mouse model of HCC provides a murine
model whereby new paradigms of HCC diagnosis and tar-
geted therapy can be evaluated [6].
The purpose of this manuscript is to evaluate modalities
of PET/CT for monitoring liver disease and HCC in
MDR2−/− mice in order to facilitate future studies aimed
at exploring experimental treatments. Previous experi-
ments using MDR2−/− mice have relied upon macroscopic
measurements of tumor burden [6]; however, using this
approach definitive assessments are only feasible at study
termination, and therefore do not provide continual mon-
itoring of disease progression and therapeutic response
during the emergence and growth of HCC.
In general, monitoring of HCC is challenging, and diag-
nosis occurs when tissue fibrosis and HCC are advanced.
However, HCC emerges in a well-defined cohort of pa-
tients with, inter alia, Hepatitis C infection (HepC), non-
alcoholic steatohepatitis (NASH) or alcoholic liver disease
(ALD) cirrhosis, providing an identifiable HCC high-risk
group. At Indiana University Hospital patients with HepC,
NASH or ALD are generally monitored twice annually for
HCC by measurement of AFP, liver biopsy histology, and
ultrasonography. Advances in imaging have moved away
from the use of ultrasonography and biopsies in favor of
PET/CT imaging [37–40, 44]. Moreover, the use of AFP
in detection of HCC has proven problematic because of
the low sensitivity and selectivity [45]. Given the afore-
mentioned limitations, this manuscript investigates PET/
CT analysis of HCC along with serum/tissue biomarkers.
The first objective of this study was to examine current
methods of HCC detection, serum AFP and PET/CT, in
MDR2−/− mice in order to illustrate compatibility and
reproducibility to that seen in patients with HCC. Previ-
ous studies have shown that AFP is reduced in response
to HCC treatment and that the level of this reduction ispredictive of survival [46]. Moreover, PET/CT is used to
diagnosis HCC and follow response to treatment [37–40].
To date HCC development has not been demonstrated in
MDR2−/− using either AFP or PET/CT.
We found that AFP generally increased contemporan-
eously with HCC levels in MDR2−/− mice consistent
with clinical studies [47], and showed moderate sensitiv-
ity and selectivity for HCC. Consequently, serum AFP
levels are a reasonable biomarker for HCC in MDR2−/−
mice and potentially could be used as a treatment response
marker. However, there was a 30 % false negative rate,
which argues that additional corroborate evidence would
be required. In the clinic, AFP is very helpful for diagnosis
and follow-up but negative AFP does not rule out the
presence of HCC.
In the current work, 11C-acetate PET/CT imaging was
shown to be a sensitive marker for monitoring HCC in
MDR2−/− mice. This was also seen with patients moni-
tored for HCC reoccurrence [39, 40]. In MDR2−/− mice
there was a significant increase in hepatic 11C-acetate
metabolic rate when compared to controls. By com-
parison, there was no corresponding increase in hep-
atic 18 F-FDG up-take in mice. This observation is similar
to previous work comparing 18 F-FDG, 6-Deoxy-6-18 F-
Fluoro-D-Glucose (18 F-6FDG) and 11C-acetate PET/CT
imaging in a hepatitis viral infection-induced woodchuck
model. Using tumor to liver uptake ratios, tumors were
detected in 53 % of animals using 18 F-FDG, 0 % using
18 F-6FDG and 94 % using 11C-acetate [48]. These data
are consistent with clinical observations of Cheung et al.
which demonstrated that 11C-acetate was far superior to
18 F-FDG for HCC detection and staging in patients prior
to liver resection or transplant [39].
Interestingly, the false negative rate of 18 F-FDG in
MDR2−/− mice is consistent with clinical evaluation of
18 F-FDG as the primary imaging biomarker in HCC in
patients [37–40]. Moreover, recent quantitative studies
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that 18 F-FDG uptake in HCC is linked to expression of
acetyl Coenzyme-A (CoA)-Synthetase-1 (ACSS1) an en-
zyme that generates acetyl-CoA from acetate and CoA,
with the hydrolysis of ATP to AMP and diphosphate
[49, 50]. In mice hepatic ACSS1 expression is relatively
low with respect to other acetyl-CoA enzymes and in
the absence of other acetyl-CoA synthesizing enzymes
ACSS1 is not sufficient to support murine development
[51]. The increase in cardiac 18 F-FDG in MDR2−/− mice
is not currently well understood, but may be linked to
an increase in glucose transporters of the heart. It is well
know that GLUT4, the main contributor of glucose
transport in the heart [52] and MDR2 are both regulated
by PI3K/AKT signaling pathway. PI3K-AKT controls the
GLUT4 translocation from intracellular vesicles to the
plasma membrane [53]. In a similar manner PI3K/AKT
activity also regulates MDR2 transporter activity [54]. At
this time no information exists pertaining to cardiac AKT
levels in MDR2−/− mice or the effect of MDR2 gene dele-
tion on cardiac GLUT4 expression; however, current re-
ports show that reduction of MDR activity with functional
inhibitors increases chemo-sensitivity without affecting
AKT phosphorylation [55]. The connection amongst
MDR2, GLUT4, and 18 F-FDG in the heart requires add-
itional investigation to better understand any interactions.
We are cognizant that observations in MDR2 gene
knockout mice may not be 100 % comparable to that seen
in patients. In MDR2−/− mice chemotherapeutic clearance
is potentially impaired, which would provide for a sus-
tained dosing time [56]. MDR2−/− mice have a significant
impairment of 99mTc-Sestamibi biliary excretion [57],
which is a marker of MDR function, and thus biliary
transport is reduced in MDR2−/− mice. However, this does
not appear to interfere with 11C-acetate PET/CT imaging
which was clearly elevated in MDR2−/− when compared
to controls. To mitigate possible hepatobiliary change in
11C-acetate transport, standardized protocols could be
used where treated and untreated groups are imaged lon-
gitudinally, thus increasing the statistical power and min-
imizing the possibility of erroneous results.
The second objective of this manuscript was to better
understand the connection between lysophosphatidic
acid (LPA) and HCC in MDR2−/− model. Previous stud-
ies have identified the biosynthesis of LPA as a marker
of HCC [58–60], and is known to be associated with tis-
sue fibrosis [61–63] in this patient population. Moreover,
we have previously shown that LPA variants were able to
differentiate between liver disease and patients with HCC
[59]. Interestingly, these data are consistent with our
current, and previous [6], studies in MDR2−/− mice where
LPA is not only elevated contemporaneous with HCC, but
the LPA 20:4 and 18:2 variants are highly consistent with
data from the clinical populations with HCC. Currentlythe precise role and mechanism connecting LPA to
HCC is not fully understood. However, LPA is known to
be associated with endothelin derived growth receptors
(EDGR) [64], and has previously been linked to cellular
signaling molecules (cAMP) and pro-inflammatory cyto-
kines (TNFα) [65, 66]. In MDR2−/− mice with HCC there
was a significant decrease in serum cAMP contemporan-
eous with an increase in LPA. The LPA receptor-3 (LPA3)
is reported to be inhibitory of adenylate cyclase activity
[64], and mice deficient in adenylate cyclase are desensi-
tized to LPA [67]. Interestingly, reductions in cAMP have
previously been reported in HCC [68]. Moreover, LPA has
also been linked to the elevated expression of TNFα [69]
which has been shown in patients with HCC [70]. In
MDR2−/− mice hepatic TNFα levels were increased con-
current with HCC and increased LPA. Combined, these
data suggests that elevated LPA biosynthesis associated
with HCC is potentially linked to modulations of cAMP
and/or TNFα. These data clearly illustrate the multitude
of pathways by which LPA can exert action within the
oncogenic milieu. These interactions are exemplified by,
inter alia, advanced glycation end products (RAGE) and
hypoxia inducible factor 1 alpha (HIF1α) which are known
to modulate cellular signaling associated with a variety of
cancer types [71, 72]. In addition to binding to EDGR re-
ceptors, LPA has also been shown to bind to the receptor
for RAGE [73], which is a key regulator of inflammation-
associated liver carcinogenesis in MDR2−/− mice [71].
Similarly, HIF1α has been shown to suppress apoptosis in
HCC cells [72] and increases cellular responsiveness to
LPA [74]. Taken overall, these data suggest that LPA plays
a key role in the development and progression of HCC in
MDR2−/− and exerts its effects via a range of second
messenger systems and/or modulation of cytokines and
growth factors.
LPA variant analysis complements 11C-acetate PET/CT
imaging. In MDR2−/− mice changes in the LPA profile
are contemporaneous with the emergence of HCC and in
patients the LPA variant profile is corrected by liver
transplantation [59]. The analysis is sensitive (nmol.ml),
standard, inexpensive and can be incorporated in to a
routine monitoring program to indicate the need for
11C-acetate PET/CT. Following LPA variant analysis
11C-acetate PET provides fmol/ml sensitivity and spatial
information in a patient population which has non-diffuse
disease, this would allow for 90Y thearaspheres or stereo-
tactic body radiotherapy to be deployed as treatment of
HCC.
Conclusion
In conclusion, there is a need for additional preclinical
studies in HCC to improve patient stratification and
treatment options. In furtherance of this goal, the current
manuscript details an evaluation of the MDR2−/− murine
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gence as monitored by serum (AFP, LPA and cAMP) and
tissue (TNFα and 11C-acetate) markers. These data cor-
roborate with previous clinical studies that show that
serum AFP, LPA and 11C-acetate PET/CT studies are
modulated following treatment [39, 46, 59] and supports
future studies to identify novel chemotherapeutics targets
for clinical trials. Going forward, and given the complex-
ity of HCC, it is unlikely that any “single surrogate bio-
marker” (or target) identified above for HCC will provide
a robust approach for monitoring disease and therapeutic
response. Moreover, we believe that advancements in the
field will rely on the strength of multiple markers in com-
bination to provide the complete picture of disease pro-
gression and response to therapies. Finally, it is our
current belief that the MDR2−/− model in combination
with validated HCC monitoring modalities will aid in
these studies.
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